Abstract: This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
Type:
Grant
Filed:
December 18, 2013
Date of Patent:
May 24, 2016
Assignee:
Alkermes Pharma Ireland Limited
Inventors:
Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
Abstract: A substrate contains a composition including VOSO4, K11H[(VO)3(SbW9O33)2], Na9[SbW9O33], oxacillin and 5-chloro-2-(2,4-dichlorophenoxy)phenol.
Type:
Grant
Filed:
January 24, 2013
Date of Patent:
May 10, 2016
Assignee:
VB JAPAN TECHNOLOGY CO., LTD.
Inventors:
Katsuaki Dan, Toshihiro Yamase, Hiromichi Ichikawa
Abstract: Articles including eartags provide topical application of a mixture of (1) a macrolide of the avermectin/milbemycin class, such as, but not limited to ivermectin, abamectin, or milbemectin, and (2) a synergist of the aryl aliphatic ether-class, such as, but not limited to piperonyl butoxide, present in (3) a weight ratio of synergist:macrolide that is greater than 1:1. The articles are effective against various pests of domestic animals, including horn flies and buffalo flies.
Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Abstract: Substrates coated with films of a ceramic material such as aluminum oxides and titanium oxides are biocompatible, and can be used in a variety of applications in which they are implanted in a living body. The substrate is preferably a porous polymer, and may be biodegradable. An important application for the ceramic-coated substrates is as a tissue engineering scaffold for forming artificial tissue.
Type:
Grant
Filed:
May 13, 2009
Date of Patent:
March 8, 2016
Assignee:
The Regents of the University of Colorado, a Body Corporate
Inventors:
Xinhua Liang, Alan W. Weimer, Stephanie J. Bryant
Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and/or water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.
Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an oxidizing biocide, and its use for the control of microorganisms in aqueous and water-containing systems.
Abstract: The invention generally relates to the fields of drug delivery and cell capture. In particular, the invention relates to amphiphilic dendron-coils, micelles thereof and their use for drug delivery vehicles and/or cell capture.
Type:
Grant
Filed:
February 22, 2012
Date of Patent:
December 15, 2015
Assignee:
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Abstract: A biologically active composition comprising an ethylcellulose, a polyethylene oxide and a biologically active ingredient, wherein the amount of ethylcellulose is at least about (15) percent, based on the total weight of the composition, can be used in melt-extrusion processes to produce pharmaceutical dosage forms.
Type:
Grant
Filed:
November 17, 2006
Date of Patent:
December 1, 2015
Inventors:
Mark J. Hall, Karen A. Coppens, Pamela S. Larsen, Shawn A. Mitchell, Michael D. Read, Uma Shrestha
Abstract: A method of treating a subject with elevated levels of peroxynitrite includes administering a therapeutically effective amount of cerium oxide nanoparticles to the subject, wherein the cerium oxide nanoparticles reduce the level of peroxynitrite in the subject.
Type:
Grant
Filed:
September 21, 2012
Date of Patent:
October 20, 2015
Assignee:
University of Central Florida Foundation, Inc.
Inventors:
William T. Self, Ella Bossy-Wetzel, Sudipta Seal, Janet Dowding
Abstract: Provided are indole alkaloid compounds of formula I, for example, pubescine, and the use of such compounds and compositions thereof to promote (e.g., enhance) melanogenesis and pigmentation. Also provided are plant extracts containing a compound of formula I, for example, pubescine, and the use of such a plant extract to promote (e.g., enhance) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.
Abstract: The present disclosure relates to drug eluting devices, and their uses. The drug eluting devices can allow for perfusion during deployment. The coatings the may contain bioactive materials which elute once deployed in a patient and can have anti-proliferative, anti-inflammation, or anti-thrombotic effects. Sol gel technology can be used to coat the devices.
Type:
Grant
Filed:
April 11, 2008
Date of Patent:
August 25, 2015
Assignee:
CELONOVA BIOSCIENCES, INC.
Inventors:
Richard Klein, John Birtles, John Koos, Michael J. Lee
Abstract: The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalevo200®. The invention also relates to processes for making such compositions.
Abstract: A method for obtaining a composite material including an aqueous solution of pectin and a suspension/solution of calcium phosphate mixed together, wherein said solution of pectin cross-links with a portion of the calcium obtained from the solution of calcium phosphate and wherein a portion of the calcium phosphate in suspension remains as inorganic phase and composite materials obtained by this method.
Abstract: In certain described embodiments, implantable medical materials comprise a scaffolding material, a liquid organic binder, and entrapped calcium-containing particles. The medical materials can incorporate an osteoinductive factor such as a protein. The scaffolding material can bind the factor. In additional described embodiments, implantable medical materials include an osteoconductive scaffolding material, an incorporated osteoinductive factor, and a biodegradable barrier material effective to delay release of the factor from the scaffolding material. The scaffolding material can bind the factor. Also described a methods for preparing and implanting the described medical materials.
Type:
Grant
Filed:
December 4, 2007
Date of Patent:
June 16, 2015
Assignee:
Warsaw Orthopedic, Inc.
Inventors:
Jeffrey M. Gross, Steve Peckham, Jeffrey Scifert, Jeffrey Badura, Nelson Scarborough, Scott Vickers
Abstract: A taste masked pharmaceutical composition of clindamycin, or a pharmaceutically acceptable salt(s), hydrate(s), solvate(s) and physiologically functional derivative(s) and precursors thereof, which includes all polymorphic forms, whether crystalline or amorphous comprising polyhydric alcohol(s); and one or more other pharmaceutically acceptable excipient(s). A process for preparation of a taste masked pharmaceutical composition of clindamycin or a pharmaceutically acceptable salt(s) thereof the said process comprising the steps of a) dry mixing clindamycin, polyhydric alcohol and other pharmaceutically acceptable excipient(s) to get a dry mixture; b) granulating the dry mixture above with a granulating liquid prepared by mixing the suitable pharmaceutically acceptable excipient(s) with aqueous/non-aqueous fluid to obtain a wet mass; c) drying the wet mass to obtain the discrete particles; d) lubricating the discrete particles obtained with a suitable lubricating agent and/or flavor(s).
Abstract: The present invention relates to a drug carrier composition comprising i) one or more biodegradable hydrating ceramics ii) one or more expandable agents, and iii) sorbed aqueous medium which in solid form has a ruptured structure. The function of the expandable agent is to create a ruptured structure in the solidified composition, either a foam-like structure or a disintegrated structure where it is split into a large number of parts, particles, units, granules or pieces, so as to obtain an enlarged apparent surface area that is exposed to degradation or erosion upon administration. Suitable substances to obtain this surface enlarging effect are gas-forming agents or swelling agents, gelling agents or disintegrants, here referred to as expandable agents. The expandable agents may be bioresorbable or non-bioresorbable.
Type:
Grant
Filed:
February 27, 2012
Date of Patent:
May 19, 2015
Assignee:
Lidds AB
Inventors:
Hans Lennernäs, Bo Lennernäs, Jonas Hugosson, Niklas Axén
Abstract: A method of forming a biocidal halogenated organic/inorganic composite material may include providing at least one inorganic precursor, providing at least one organic agent, precipitating an organic/inorganic composite material by contacting the at least one inorganic precursor with the at least one organic agent, and halogenating the organic/inorganic composite material by contacting the organic/inorganic composite material with a halogen. Also, a halogenated organic/inorganic composite material may include an inorganic composition comprising a metal oxide and a halogenated organic composition. The inorganic composition and the halogenated organic composition are dispersed throughout the composite material.